Use of zoledronate for treatment of a bone fragility disorder in horses

Scott A Katzman, Jorge Nieto, Amanda M. Arens, Melinda H. MacDonald, Sarah M. Puchalski, Larry D Galuppo, Jack R. Snyder, Omar Maher, Robin J W Bell

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective-To assess clinical outcomes and scintigraphic findings in horses with a bone fragility disorder (BFD) treated with zoledronate (a nitrogen-containing bisphosphonate). Design-Prospective uncontrolled clinical trial Animals-10 horses with evidence of a BFD. Procedures-Signalment, history, and geographic location of horses' home environments were recorded. Physical examinations, lameness evaluations, and nuclear scintigraphy were performed. Diagnosis of a BFD was made on the basis of results of clinical and scintigraphic examination. Each horse was treated with zoledronate (0.075 mg/kg [0.034 mg/ lb, IV, once]) at the time of diagnosis. Horses were reevaluated 6 months after treatment. Results-Affected horses were from the central and coastal regions of California and had > 1 clinical sign of the disorder; these included scapular deformation (n = 2), lordosis (1), nonspecific signs of musculoskeletal pain (1), and lameness that could not be localized to a specific anatomic region (9). All horses had multiple sites of increased radiopharmaceutica uptake during initial scintigraphic evaluation of the axial skeleton and bones of 1 or both forelimbs. Six months after treatment, clinical improvement (defined as improvement in the lameness score, resolution of signs of musculoskeletal pain, or both) was detected in 9 of 10 horses; scintigraphic uptake was unchanged (n = 2) or subjectively decreased (8). No adverse effects attributed to zoledronate treatment were detected. Conclusions and Clinical Relevance-Treatment with zoledronate appeared to be useful in improving clinical outcome and scintigraphic findings in horses with a BFD; however, future placebo-controlled studies are necessary to accurately determine efficacy and long-term safety.

Original languageEnglish (US)
Pages (from-to)1323-1328
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume240
Issue number11
DOIs
StatePublished - Jun 1 2012

Fingerprint

zoledronic acid
Horses
bones
horses
Bone and Bones
lameness
Musculoskeletal Pain
Therapeutics
pain
uptake mechanisms
Geographic Locations
Lordosis
scintigraphy
Forelimb
Diphosphonates

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Use of zoledronate for treatment of a bone fragility disorder in horses. / Katzman, Scott A; Nieto, Jorge; Arens, Amanda M.; MacDonald, Melinda H.; Puchalski, Sarah M.; Galuppo, Larry D; Snyder, Jack R.; Maher, Omar; Bell, Robin J W.

In: Journal of the American Veterinary Medical Association, Vol. 240, No. 11, 01.06.2012, p. 1323-1328.

Research output: Contribution to journalArticle

Katzman, Scott A ; Nieto, Jorge ; Arens, Amanda M. ; MacDonald, Melinda H. ; Puchalski, Sarah M. ; Galuppo, Larry D ; Snyder, Jack R. ; Maher, Omar ; Bell, Robin J W. / Use of zoledronate for treatment of a bone fragility disorder in horses. In: Journal of the American Veterinary Medical Association. 2012 ; Vol. 240, No. 11. pp. 1323-1328.
@article{0694a6c8a4e0448385676e6519d1ed87,
title = "Use of zoledronate for treatment of a bone fragility disorder in horses",
abstract = "Objective-To assess clinical outcomes and scintigraphic findings in horses with a bone fragility disorder (BFD) treated with zoledronate (a nitrogen-containing bisphosphonate). Design-Prospective uncontrolled clinical trial Animals-10 horses with evidence of a BFD. Procedures-Signalment, history, and geographic location of horses' home environments were recorded. Physical examinations, lameness evaluations, and nuclear scintigraphy were performed. Diagnosis of a BFD was made on the basis of results of clinical and scintigraphic examination. Each horse was treated with zoledronate (0.075 mg/kg [0.034 mg/ lb, IV, once]) at the time of diagnosis. Horses were reevaluated 6 months after treatment. Results-Affected horses were from the central and coastal regions of California and had > 1 clinical sign of the disorder; these included scapular deformation (n = 2), lordosis (1), nonspecific signs of musculoskeletal pain (1), and lameness that could not be localized to a specific anatomic region (9). All horses had multiple sites of increased radiopharmaceutica uptake during initial scintigraphic evaluation of the axial skeleton and bones of 1 or both forelimbs. Six months after treatment, clinical improvement (defined as improvement in the lameness score, resolution of signs of musculoskeletal pain, or both) was detected in 9 of 10 horses; scintigraphic uptake was unchanged (n = 2) or subjectively decreased (8). No adverse effects attributed to zoledronate treatment were detected. Conclusions and Clinical Relevance-Treatment with zoledronate appeared to be useful in improving clinical outcome and scintigraphic findings in horses with a BFD; however, future placebo-controlled studies are necessary to accurately determine efficacy and long-term safety.",
author = "Katzman, {Scott A} and Jorge Nieto and Arens, {Amanda M.} and MacDonald, {Melinda H.} and Puchalski, {Sarah M.} and Galuppo, {Larry D} and Snyder, {Jack R.} and Omar Maher and Bell, {Robin J W}",
year = "2012",
month = "6",
day = "1",
doi = "10.2460/javma.240.11.1323",
language = "English (US)",
volume = "240",
pages = "1323--1328",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "11",

}

TY - JOUR

T1 - Use of zoledronate for treatment of a bone fragility disorder in horses

AU - Katzman, Scott A

AU - Nieto, Jorge

AU - Arens, Amanda M.

AU - MacDonald, Melinda H.

AU - Puchalski, Sarah M.

AU - Galuppo, Larry D

AU - Snyder, Jack R.

AU - Maher, Omar

AU - Bell, Robin J W

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Objective-To assess clinical outcomes and scintigraphic findings in horses with a bone fragility disorder (BFD) treated with zoledronate (a nitrogen-containing bisphosphonate). Design-Prospective uncontrolled clinical trial Animals-10 horses with evidence of a BFD. Procedures-Signalment, history, and geographic location of horses' home environments were recorded. Physical examinations, lameness evaluations, and nuclear scintigraphy were performed. Diagnosis of a BFD was made on the basis of results of clinical and scintigraphic examination. Each horse was treated with zoledronate (0.075 mg/kg [0.034 mg/ lb, IV, once]) at the time of diagnosis. Horses were reevaluated 6 months after treatment. Results-Affected horses were from the central and coastal regions of California and had > 1 clinical sign of the disorder; these included scapular deformation (n = 2), lordosis (1), nonspecific signs of musculoskeletal pain (1), and lameness that could not be localized to a specific anatomic region (9). All horses had multiple sites of increased radiopharmaceutica uptake during initial scintigraphic evaluation of the axial skeleton and bones of 1 or both forelimbs. Six months after treatment, clinical improvement (defined as improvement in the lameness score, resolution of signs of musculoskeletal pain, or both) was detected in 9 of 10 horses; scintigraphic uptake was unchanged (n = 2) or subjectively decreased (8). No adverse effects attributed to zoledronate treatment were detected. Conclusions and Clinical Relevance-Treatment with zoledronate appeared to be useful in improving clinical outcome and scintigraphic findings in horses with a BFD; however, future placebo-controlled studies are necessary to accurately determine efficacy and long-term safety.

AB - Objective-To assess clinical outcomes and scintigraphic findings in horses with a bone fragility disorder (BFD) treated with zoledronate (a nitrogen-containing bisphosphonate). Design-Prospective uncontrolled clinical trial Animals-10 horses with evidence of a BFD. Procedures-Signalment, history, and geographic location of horses' home environments were recorded. Physical examinations, lameness evaluations, and nuclear scintigraphy were performed. Diagnosis of a BFD was made on the basis of results of clinical and scintigraphic examination. Each horse was treated with zoledronate (0.075 mg/kg [0.034 mg/ lb, IV, once]) at the time of diagnosis. Horses were reevaluated 6 months after treatment. Results-Affected horses were from the central and coastal regions of California and had > 1 clinical sign of the disorder; these included scapular deformation (n = 2), lordosis (1), nonspecific signs of musculoskeletal pain (1), and lameness that could not be localized to a specific anatomic region (9). All horses had multiple sites of increased radiopharmaceutica uptake during initial scintigraphic evaluation of the axial skeleton and bones of 1 or both forelimbs. Six months after treatment, clinical improvement (defined as improvement in the lameness score, resolution of signs of musculoskeletal pain, or both) was detected in 9 of 10 horses; scintigraphic uptake was unchanged (n = 2) or subjectively decreased (8). No adverse effects attributed to zoledronate treatment were detected. Conclusions and Clinical Relevance-Treatment with zoledronate appeared to be useful in improving clinical outcome and scintigraphic findings in horses with a BFD; however, future placebo-controlled studies are necessary to accurately determine efficacy and long-term safety.

UR - http://www.scopus.com/inward/record.url?scp=84861473294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861473294&partnerID=8YFLogxK

U2 - 10.2460/javma.240.11.1323

DO - 10.2460/javma.240.11.1323

M3 - Article

C2 - 22607600

AN - SCOPUS:84861473294

VL - 240

SP - 1323

EP - 1328

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 11

ER -